- Trial phase
- Approved (generic, off-patent)
- Time to market
- Already on market since 1996 (Norvir); generic widely available.
- Why 2/10
- Ritonavir is an old, generic, off-patent drug that Enanta does not develop, own, or commercialize. There is no upcoming hard, dated catalyst for ritonavir. The two patent-litigation events tied to ritonavir-containing products (US Federal Circuit ruling in June 2026 and UPC ruling on October 29, 2026) have already occurred and were negative for Enanta. With no pending binary catalyst for this drug, the impact score is low.
Ritonavir itself is not an Enanta catalyst. The two patent-litigation "lottery tickets" tied to ritonavir-containing products have now both come up empty: the US patent was invalidated in June 2026 and the EU patent was revoked on October 29, 2026. Enanta's next meaningful binary catalyst is the Phase 2b data readout from the RESOLVE trial of zelicapavir for RSV, expected in 2027. The company also reports fiscal Q4 2026 earnings on November 16, 2026, which will show the continuing trajectory of its declining HCV royalty revenue.
Price Chart
Executive Summary
Ritonavir is an old, widely genericized HIV protease inhibitor (brand name Norvir, originally by Abbott/AbbVie) that is not a drug Enanta Pharmaceuticals develops, owns, or commercializes. Enanta's connection to ritonavir is indirect: (1) historically, Enanta-discovered HCV protease inhibitors were co-formulated with ritonavir as a pharmacokinetic booster in AbbVie's now-obsolete hepatitis C products Technivie and Viekira Pak/Xr; and (2) Enanta sued Pfizer alleging Paxlovid (nirmatrelvir co-packaged with ritonavir) infringed its patents. Enanta lost that litigation on both sides of the Atlantic: the US Federal Circuit affirmed patent invalidity in June 2026, and the Unified Patent Court revoked the European counterpart on October 29, 2026, just one day before this report. Enanta's current business is focused on its own RSV pipeline (zelicapavir in Phase 2b/3, EDP-323 in Phase 2) and immunology programs, with revenue from declining HCV royalties on AbbVie's MAVYRET/MAVIRET (which does not contain ritonavir).
How It Works
Ritonavir is an HIV protease inhibitor, meaning it blocks a viral enzyme the HIV virus needs to replicate. In modern practice it is used almost exclusively as a "booster" (pharmacokinetic enhancer) at low doses: it inhibits a liver enzyme (CYP3A4) that would otherwise break down other antiviral drugs, raising their blood levels and allowing lower, less frequent dosing. This boosting role is why ritonavir appears as a component in several combination products, including AbbVie's former HCV regimens and Pfizer's COVID-19 antiviral Paxlovid.
Trial Status
Ritonavir was first approved by the FDA in 1996 as Norvir for HIV/AIDS. It is now off-patent and widely available as a generic. It is not an active development candidate at Enanta or any other company; its role is as an established pharmacokinetic booster in fixed-dose combination products developed by other firms.
The Two-Sided Case
Upcoming Catalysts
- No upcoming catalysts for ritonavir itself. Enanta's next catalysts are: fiscal Q4 2026 earnings (November 16, 2026) and Phase 2b data from the zelicapavir RESOLVE RSV trial (expected 2027).
Source Filing
The SecBot filing or press-release report that triggered this drug report:
ENANTA PHARMACEUTICALS INC 8-K ENTA ·Originating report